David A. Siegel Acelrx Pharmaceuticals Inc Transaction History

Two Sigma Advisers, LP

8 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q2 2021 Aug 16, 2021	SELL	$1.03 - $1.7 $42,127 - $69,530	-40,900 Closed	0 $0
Q1 2021 May 17, 2021	BUY	$1.25 - $2.77 $51,125 - $113,293	40,900 New	40,900 $70,000
Q4 2020 Feb 16, 2021	SELL	$1.18 - $1.98 $28,084 - $47,124	-23,800 Closed	0 $0
Q3 2020 Nov 16, 2020	SELL	$1.01 - $1.81 $16,261 - $29,141	-16,100 Reduced 40.35%	23,800 $34,000
Q2 2020 Aug 14, 2020	BUY	$1.03 - $1.69 $41,097 - $67,431	39,900 New	39,900 $48,000
Q2 2019 Aug 14, 2019	SELL	$2.1 - $3.93 $95,270 - $178,292	-45,367 Closed	0 $0
Q1 2019 May 15, 2019	BUY	$2.35 - $3.83 $16,062 - $26,178	6,835 Added 17.74%	45,367 $158,000
Q4 2018 Feb 14, 2019	BUY	$2.13 - $4.8 $82,073 - $184,953	38,532 New	38,532 $89,000

Ticker ACRX
Exchange NASDAQ
Sector Healthcare
Industry Drug Manufacturers—Specialty & Generic
Shares Outstandng 7,366,600
Market Cap $8.32M
Description
AcelRx Pharmaceuticals, Inc., a specialty pharmaceutical company, focuses on the development and commercialization of therapies for the treatment of acute pain. Its lead product candidate is DSUVIA and DZUVEO, a 30 mcg sufentanil sublingual tablet for the treatment of moderate-to-severe acute pain. The company develops ZALVISO, a pre-programmed ...

Get notified when there are updates to the investment portfolio of Two Sigma Advisers, LP, based on Form 13F filings with the SEC.

Stay updated on Two Sigma Advisers, LP and David A. Siegel with notifications on news.